Predicted protein targets (top 6)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | L3MBTL1 | Q9Y468 | 1/20 | 0.36 |
| ▸ | KDM4E | B2RXH2 | 2/20 | 0.35 |
| ▸ | ADRA1D | P25100 | 1/20 | 0.33 |
| ▸ | PARP1 | P09874 | 1/20 | 0.32 |
| ▸ | MEN1 | O00255 | 1/20 | 0.31 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.31 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL23772086 | 0.83 | GLRA3 (0.37) | KDM4EMEN1KMT2A | |
| SCHEMBL23771938 | 0.79 | BRD4 (0.41) | L3MBTL1KDM4E | |
| SCHEMBL5205237 | 0.77 | KDM4E (0.37) | L3MBTL1KDM4EADRA1DPARP1MEN1 | |
| SCHEMBL4659254 | 0.76 | SCN9A (0.37) | KDM4EPARP1MEN1KMT2A | |
| SCHEMBL23772007 | 0.76 | L3MBTL1 (0.37) | L3MBTL1PARP1MEN1KMT2A | |
| SCHEMBL23772031 | 0.74 | MYC (0.38) | — | |
| SCHEMBL29812378 | 0.69 | BCAT2 (0.51) | KDM4EMEN1KMT2A | |
| Hydrochloric Acid SCHEMBL29812299 | 0.68 | BCAT2 (0.50) | KDM4EMEN1KMT2A | |
| SCHEMBL15328107 | 0.67 | MET (0.50) | MEN1KMT2A | |
| SCHEMBL14506376 | 0.67 | ALDH1A1 (0.38) | KDM4E |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 1 patent. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20210251991-A1 | SUBSTITUTED 2,2'-BIPYRIMIDINYL COMPOUNDS, ANALOGUES THEREOF, AND METHODS USING SAME | ARBUTUS BIOPHARMA CORPORATION (CA) | 2021-08-19 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20210251991-A1 | SUBSTITUTED 2,2'-BIPYRIMIDINYL COMPOUNDS, ANALOGUES THEREOF, AND METHODS USING SAME | HAVCR2, CDV3, HMBS | L3MBTL1 1044/4885KDM4E 1113/4885ADRA1D 4602/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.